Compare Heron Therapeutics Inc (HRTX) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Invesco NASDAQ 100 ETF — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Invesco NASDAQ 100 ETF trades at $308.93 (market cap $113.40B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 1667.4× Heron Therapeutics Inc's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Invesco NASDAQ 100 ETF for 54 Days on average.
| HRTX | QQQM | |
|---|---|---|
Market Cap | $68.01M | $113.40B |
Volume | 1,891,941 | 2,866,236 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.49 | $312.76 |
52-Week Low | $0.27 | $229.87 |
Typical Hold Time | 35 Days | 54 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
QQQM trades at $308.42, down 1.15% on the day, while maintaining a bullish technical outlook with strong moving average support. The ETF's lower 0.15% expense ratio compared to QQQ's 0.18% provides a cost advantage, though trading spreads can impact returns. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026, signaling confidence in the Nasdaq-100 exposure.
The ETF offers pure Nasdaq-100 exposure with competitive fees, though investors should be aware of concentration risk in technology stocks and potential tax implications of distributions. Technical indicators suggest near-term support at $305 with resistance at $311, while institutional accumulation supports the bullish case for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
